Trade Gilead Sciences Inc - GILD CFD

Gilead Company profile

What is Gilead Sciences?

Gilead Sciences Inc. is a US biopharmaceutical company. Following a series of mergers and acquisitions, Gilead is now one of the biggest players in its field with almost 9,000 employees working all over the globe. A portfolio of shipped products includes medicals for HIV treatment and HIV prevention. Gilead focuses on medical products that serve to cure oncology, liver diseases, cardiovascular disorders and many other severe health conditions. Gilead has a wide network of partnerships and collaborations.
 

What does the company do?

A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.

The portfolio of Gilead’s products and investigational drugs includes innovative treatments for AIDS/HIV, cancer, respiratory, inflammatory, liver diseases and cardiovascular conditions.
 

A bit of Gilead Sciences’ history

Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.

 

Who founded Gilead Sciences?

Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.

 

Establishing the company and its vision, Michael L. Riordan collaborated with three major scientific advisors, including Doug Melton of Harvard, Peter Dervan of Caltech and Harold Weintraub of the Fred Hutchinson Cancer Research Center.
 
A venture capital firm Menlo Ventures, where Riordan worked for one year, made the first investment of $2 million into Gilead Sciences.
 

Current size, team and locations

Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.

 

Quick facts about Gilead Sciences

  • Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
  • It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
  • In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
  • In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.

How to learn the Gilead Sciences share price?

Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the US Tech 100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.

Latest shares articles

ECB Preview: cooling growth and inflation call for another rate cut
Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.
14:15, 16 October 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:41, 11 September 2024
Stocks struggle for direction as US jobs data fails to give assurance
Traders struggle to find a direction as the latest US jobs data gives a mixed picture heading into the FOMC September meeting.
13:32, 6 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
09:13, 29 August 2024

Read our reviews to find out more about us

Read the feedback from our clients around the world.
2024-10-22
infoaamon

Very trustworthy and affordable for any size trades

2024-10-21
remi74

It is very easy to connect with TradingView but the web interface is also great.

2024-10-15
jdancer37

Easy to use and great support. Been using it for 2 years already and still happy

2024-10-14
DANIEL

Capital.com is one of the best stock trading platforms I’ve used. The UX and UI on both the mobile app and web platform are outstanding, making it incredibly easy to navigate. They’ve built a vibrant community of traders and investors, and their UAE team really stands out for delivering an exceptional trading experience.

2024-10-08
Yahyaamez

Best broker!! they call you to see if you need any help. The app is good and nice better than the rest

2024-10-04
Iuliia Salivon

Great app! I requested some features to be added, such as analysis tools, and they delivered. Amazing job! The agents are always helpful and reply quickly. It’s not 5 stars because, at times, some less experienced agents may say it’s impossible to fulfill the request or fix the problem while another agent, like Angel, quickly escalated the issue to the necessary team/person/department and resolved it

2024-10-04
Moh ST

This is an excellent platform. The stop loss and take profit work very well; however, when the changes are very fast like at the beginning of the session, the stop loss does not work. If this defect is corrected it will be the perfect platform.

2024-09-30
adenysenko24

-Nice -Easy to use - Beautiful Interface

2024-09-26
Daniel

I think I'm new in this trading platform, but I find it affordable and most reliable. To be honest I'm not fully experienced trader, but with very limited knowledge of trading I try learn as much as I can by trying out different platforms see if can make money. My interests growing in you platform, l like news updates you also short videos on YouTube, other propaganda, poster and many more. I will see what happens in the coming months. Thanks capital team.

2024-09-26
John Fallows

Gives you options to start learning how too do it as it gives you a demo option to learn from your mistakes

2024-09-24
PHEMELO

Efficiency. When creating the account, it was smooth, efficient from start to finish. Verification of documents also was done the same day, unlike other platforms where you have to wait a day or two.

2024-09-04
Osondu Paul

From what I'm seeing it's cool Mixing it with trading view it's perfect... I didn't give it 5 star yet cos I still need to use it for some time

Showing our 4 & 5 star reviews

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading